{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:42:02Z","timestamp":1764175322471,"version":"3.37.3"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"4","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8150111724"],"award-info":[{"award-number":["8150111724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Fund for Cancer Prevention and Treatment of Shan dong Natural Fund","award":["ZR2019LZL015"],"award-info":[{"award-number":["ZR2019LZL015"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Projects of China","doi-asserted-by":"publisher","award":["2018YFC1312201"],"award-info":[{"award-number":["2018YFC1312201"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Radiation Oncology Innovate Unit, Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2019RU071"],"award-info":[{"award-number":["2019RU071"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015507","name":"Academic Promotion Program of Shandong First Medical University","doi-asserted-by":"publisher","award":["2019ZL002"],"award-info":[{"award-number":["2019ZL002"]}],"id":[{"id":"10.13039\/501100015507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"foundation of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972863","81627901","82030082"],"award-info":[{"award-number":["81972863","81627901","82030082"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"CSCO-2019 Hausen Oncology Research Fund Project","doi-asserted-by":"publisher","award":["Y-HS2019-52"],"award-info":[{"award-number":["Y-HS2019-52"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2018GSF118097"],"award-info":[{"award-number":["2018GSF118097"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Thymic epithelial tumors (TETs) are rare thoracic malignancies with no\nstandard second-line treatment. Tumor angiogenesis is closely associated with the pathogenesis and\ninvasiveness of TETs. Anlotinib is a small-molecule multitarget tyrosine kinase inhibitor (TKI)\nwhich inhibits tumor angiogenesis and tumor cell proliferation. Published studies have demonstrated\nthe promising clinical effect of multitarget TKIs sunitinib and lenvatinib in previously treated TETs.\nHowever, TKIs have a high incidence of adverse events (AEs).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this study, we investigated the clinical efficacy and safety of anlotinib in previously\ntreated TET patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We collected clinical data of 22 patients from Shandong Cancer Hospital and Institute\nbetween October 2018 and March 2022. These patients were diagnosed with advanced TETs and\nreceived at least the first-line (1st-line) treatment. We analyzed the clinical effects between anlotinib\nmonotherapy and anlotinib combination therapy in the second-line (2nd-line) or anlotinib\ntreatment in different lines.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>These 22 patients included 18 cases of thymic carcinoma (TC) and 4 cases of thymoma\n(T). 68.2% of patients were males, and the median age was 53 years. Fourteen patients (63.6%)\nreceived anlotinib monotherapy and 8 patients (36.4%) received anlotinib combination therapy.\nThe objective response rate (ORR) was 9.1% in the overall patients. The median progression-free\nsurvival (PFS) in the overall population was 12 months (14 months for T and 9 months for TC),\nand the median overall survival (OS) was 24 months (survival was not reached for T and was 24\nmonths for TC). The incidence of AEs was 50%, most of them were grades I and II, and the incidence\nof grades III and IV AEs was 9%.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This is the first study reporting the clinical effect of anlotinib in previously treated\nTETs patients. The survival data indicate that the efficacy of anlotinib is superior to sunitinib and\nlenvatinib. Our results suggest that anlotinib is a promising treatment option for previously treated\nTET patients and its toxicity is tolerable. More research and patents are needed in the future to\nexplore better options for the diagnosis and treatment of TETs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574892818666221122114753","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:33:51Z","timestamp":1669178031000},"page":"528-537","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Efficacy and Safety of Anlotinib Alone and in Combination with\nOther Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A\nRetrospective Analysis"],"prefix":"10.2174","volume":"18","author":[{"given":"Shuo","family":"Li","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,\nShandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical\nUniversity and Shandong Academy of Medical Science, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiqin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical\nUniversity and Shandong Academy of Medical Science, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical\nUniversity and Shandong Academy of Medical Science, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongjie","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical\nUniversity and Shandong Academy of Medical Science, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical\nUniversity and Shandong Academy of Medical Science, Jinan, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan,\nShandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/jjco\/hyx138","volume":"47","author":"Yokoi K.","year":"2017","unstructured":"Yokoi K.; Kondo K.; Fujimoto K.; et al. JLCS medical practice guidelines for thymic tumors: summary of recommendations. Jpn J Clin Oncol 2017,47(12),1119-1122","journal-title":"Jpn J Clin Oncol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","volume":"10","author":"Marx A.","year":"2015","unstructured":"Marx A.; Chan J.K.C.; Coindre J.M.; et al. The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes. J Thorac Oncol 2015,10(10),1383-1395","journal-title":"J Thorac Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","volume":"89","author":"Margaritora S.","year":"2010","unstructured":"Margaritora S.; Cesario A.; Cusumano G.; et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. Ann Thorac Surg 2010,89(1),245-252","journal-title":"Ann Thorac Surg"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"Girard N.","year":"2015","unstructured":"Girard N.; Ruffini E.; Marx A.; Faivre-Finn C.; Peters S.; Committee E.G.; Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015,26(Suppl. 5),v40-v55","journal-title":"Ann Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2016.06.020","volume":"99","author":"Bluthgen M.V.","year":"2016","unstructured":"Bluthgen M.V.; Boutros C.; Fayard F.; Remon J.; Planchard D.; Besse B.; Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. Lung Cancer 2016,99,111-116","journal-title":"Lung Cancer"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.jtho.2018.07.094","volume":"13","author":"Gbolahan O.B.","year":"2018","unstructured":"Gbolahan O.B.; Porter R.F.; Salter J.T.; et al. A Phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. J Thorac Oncol 2018,13(12),1940-1948","journal-title":"J Thorac Oncol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","volume":"13","author":"Merveilleux du Vignaux C.","year":"2018","unstructured":"Merveilleux du Vignaux C.; Dansin E.; Mhanna L.; Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort. J Thorac Oncol 2018,13(11),1762-1770","journal-title":"J Thorac Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","volume":"36","author":"Zucali P.A.","year":"2018","unstructured":"Zucali P.A.; De Pas T.; Palmieri G.; et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2018,36(4),342-349","journal-title":"J Clin Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.aanat.2007.05.003","volume":"190","author":"Cimpean A.M.","year":"2008","unstructured":"Cimpean A.M.; Raica M.; Encica S.; Cornea R.; Bocan V.; Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008,190(3),238-245","journal-title":"Ann Anat"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1067\/mtc.2002.124389","volume":"124","author":"Tomita M.","year":"2002","unstructured":"Tomita M.; Matsuzaki Y.; Edagawa M.; et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002,124(3),493-498","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s005950170021","volume":"31","author":"Sasaki H.","year":"2001","unstructured":"Sasaki H.; Kobayashi Y.; Nakashima Y.; et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001,31(11),1038-1040","journal-title":"Surg Today"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","volume":"97","author":"Remon J.","year":"2016","unstructured":"Remon J.; Girard N.; Mazieres J.; Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network. Lung Cancer 2016,97,99-104","journal-title":"Lung Cancer"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","volume":"21","author":"Sato J.","year":"2020","unstructured":"Sato J.; Satouchi M.; Itoh S.; et al. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. Lancet Oncol 2020,21(6),843-850","journal-title":"Lancet Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","volume":"16","author":"Thomas A.","year":"2015","unstructured":"Thomas A.; Rajan A.; Berman A.; et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015,16(2),177-186","journal-title":"Lancet Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/cas.13536","volume":"109","author":"Xie C.","year":"2018","unstructured":"Xie C.; Wan X.; Quan H.; et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor\u20102 inhibitor. Cancer Sci 2018,109(4),1207-1219","journal-title":"Cancer Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","volume":"18","author":"Huinen Z.R.","year":"2021","unstructured":"Huinen Z.R.; Huijbers E.J.M.; van Beijnum J.R.; Nowak-Sliwinska P.; Griffioen A.W.; Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 2021,18(8),527-540","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"Liu S.","year":"2020","unstructured":"Liu S.; Qin T.; Liu Z.; et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 2020,11(5),309","journal-title":"Cell Death Dis"},{"year":"2019","author":"Palakurthi S","key":"ref=18","unstructured":"Palakurthi S; Kuraguchi M; Zacharek SJ; et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumorintrinsic induction of antitumor immunity. cancer immunol Res 2019; 7(9): 1457-71. http:\/\/dx.doi.org\/10.1158\/2326-6066.CIR-18-0595 PMID: 31331945 2019"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ol.2020.11685","volume":"20","author":"Gao Y.","year":"2020","unstructured":"Gao Y.; Liu P.; Shi R.; Anlotinib as a molecular targeted therapy for tumors. (Review) Oncol Lett 2020,20(2),1001-1014","journal-title":"Oncol Lett"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1111\/1759-7714.13658","volume":"11","author":"Zuo R.","year":"2020","unstructured":"Zuo R.; Zhang C.; Lin L.; et al. Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review. Thorac Cancer 2020,11(11),3383-3387","journal-title":"Thorac Cancer"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.2147\/CMAR.S362858","volume":"14","author":"Qin W","year":"2022","unstructured":"Qin W; Zou B; Fan X; Fan B; Wang S; Wang L; Transformation from small cell to squamous cell carcinoma in a thymic carcinoma patient with a durable response to anlotinib: a case report. cancer Manag Res  2022,14,1595-602"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1177\/030089161309900428","volume":"99","author":"Watanabe K.","year":"2013","unstructured":"Watanabe K.; Shinkai M.; Goto H.; et al. Chemotherapy with carboplatin and paclitaxel after failure of primary chemotherapy for advanced thymic carcinoma. A report of three cases and review of the literature. Tumori 2013,99(4),e172-e176","journal-title":"Tumori"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1634\/theoncologist.2019-0593","volume":"25","author":"Tateishi K.","year":"2020","unstructured":"Tateishi K.; Ko R.; Shukuya T.; et al. Clinical outcomes of second-line chemotherapy in patients with previously treated advanced thymic carcinoma: a retrospective analysis of 191 patients from the NEJ023 Study. Oncologist 2020,25(4),e668-e674","journal-title":"Oncologist"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12885-016-2159-7","volume":"16","author":"Okuma Y.","year":"2016","unstructured":"Okuma Y.; Hosomi Y.; Miyamoto S.; Shibuya M.; Okamura T.; Hishima T.; Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma. BMC Cancer 2016,16(1),156","journal-title":"BMC Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","volume":"37","author":"Cho J.","year":"2019","unstructured":"Cho J.; Kim H.S.; Ku B.M.; et al. Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 2019,37(24),2162-2170","journal-title":"J Clin Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","volume":"16","author":"Giaccone G.","year":"2021","unstructured":"Giaccone G.; Kim C.; durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up. J Thorac Oncol 2021,16(3),483-485","journal-title":"J Thorac Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","volume":"19","author":"Giaccone G.","year":"2018","unstructured":"Giaccone G.; Kim C.; Thompson J.; et al. Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018,19(3),347-355","journal-title":"Lancet Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","volume":"113","author":"Katsuya Y.","year":"2019","unstructured":"Katsuya Y.; Horinouchi H.; Seto T.; et al. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 2019,113,78-86","journal-title":"Eur J Cancer"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","volume":"7","author":"Rajan A.","year":"2019","unstructured":"Rajan A.; Heery C.R.; Thomas A.; et al. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma. J Immunother Cancer 2019,7(1),269","journal-title":"J Immunother Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAI.0000000000000699","volume":"28","author":"Bedekovics J.","year":"2020","unstructured":"Bedekovics J.; Beke L.; Mokanszki A.; Szilagyi S.; Mehes G.; Programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors. Appl Immunohistochem Mol Morphol 2020,28(1),1-9","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.21037\/jtd-21-290","volume":"13","author":"Song X.","year":"2021","unstructured":"Song X.; Fan J.; Zhu L.; Wang Z.; He Y.; Zhou C.; The efficacy and safety of immunotherapy in thymic epithelial tumors: more effective, more risky: a systematic review. J Thorac Dis 2021,13(8),5093-5103","journal-title":"J Thorac Dis"},{"year":"2022","author":"Williams E.","key":"ref=32","unstructured":"Williams E.;  KMT2A-MAML2 fusion molecules and uses thereof. US202202902532022"},{"year":"2021","author":"Williams E.","key":"ref=33","unstructured":"Williams E.; KMT2A-MAML2 fusion molecules and uses thereof. US20220290253, 2021"},{"year":"2014","author":"Dudakov J","key":"ref=34","unstructured":"Dudakov J; Van D; Brink M; Hanash A; Methods of use for IL-22 promoting rejuvenation of thymic and bone marrow function. US20140248235, 2014"},{"year":"2022","author":"Irla M","key":"ref=35","unstructured":"Irla M; Lopes N; Methods of boosting thymic regeneration in patients suffering from a thymic injury by using RANKL. US20220265768, 2022"},{"year":"2020","author":"Dudakov J","key":"ref=36","unstructured":"Dudakov J; Van D; Brink M; Wertheimer T.; Use of BMP4 for thymic regeneration. 10619134, 2020"},{"year":"2015","author":"Dudakov J","key":"ref=37","unstructured":"Dudakov J; Van D; Brink M; Hanash A; Methods of use for IL-22 promoting rejuvenation of thymic and bone marrow function. 9119824, 2015"},{"year":"2016","author":"Serwold T","key":"ref=38","unstructured":"Serwold T; Lee RT; Wagers A; Thymic Regeneration. US20160120945, 2016"},{"year":"2003","author":"Reinherz EL","key":"ref=39","unstructured":"Reinherz EL; Sasada T; Wang J; Polypeptides and methods for thymic vaccination. US20030082156, 2003"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892818666221122114753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/211116\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574892818666221122114753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T15:58:03Z","timestamp":1692892683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/211116\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574892818666221122114753","relation":{},"ISSN":["1574-8928"],"issn-type":[{"type":"print","value":"1574-8928"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}